OHSU clinical trial validates new, FDA-cleared technique for knee repair

This week’s FDA granting of marketing authorization of implantable shock absorber marks first new surgical treatment in decades for osteoarthritis of the knee

By Erik Robinson April 12, 2023 Portland, Oregon

Lea esta página en español

Downloads

Knee implant - Moximed

A new treatment approach could improve the lives of millions of people afflicted with osteoarthritis of the knee. (Moximed)

Moximed

A new treatment approach could improve the lives of millions of people afflicted with osteoarthritis of the knee. (Moximed)

Dennis Crawford M.D., Ph.D. (OHSU)

Karla Hunt, back in action

Karla Hunt stands atop a peak in Scotland in 2017, a few weeks after undergoing a surgical treatment for osteoarthritis in the knees at OHSU. Hunt underwent the procedure as part of a nationwide clinical trial validating a new implantable shock absorber for the knee known as MISHA. Now FDA-approved, OHSU expects to be able to offer the procedure routinely in the coming months. (Courtesy)